Medicines for Malaria Venture (MMV)

30/09/2025

What does it take to end and rewrite the future?

Collaboration. Innovation. Openness. Equity.

These essential elements are the values that guide MMV’s work – uniting our team, shaping our partnerships and keeping us focused on our mission: a malaria-free future.

Together, we can end malaria – will you join us?

29/09/2025

At a moment when the global health community must accelerate progress and deliver innovations to strengthen health security, investing in proven initiatives and advancing R&D is critical.

The Gates Foundation is meeting this moment and building momentum for a healthier future with a $912 million pledge to The Global Fund. This will help save millions more lives from , and , and protect decades of global health progress.

MMV welcomes this commitment and stands by the fact that we all have a stake in building a healthier world.

Read about this 3-year pledge and why “we can’t stop at almost.”
👉 bit.ly/4nkCfB4

26/09/2025

Malaria prevention tools – seasonal malaria chemoprevention (SMC), vector control and – save lives, and their impact is even greater when used together.

A new systematic review published in PLOS Health confirms that SMC significantly reduces -related illness and death among children under five in Africa’s Sahel region.

The findings highlight both the challenges to scaling SMC – including logistics, adherence and reaching children in remote areas – and the opportunity to save more lives by integrating SMC with complementary prevention tools to achieve a synergistic impact.

👉 Learn more: bit.ly/46wcCGB

24/09/2025

What role can AI and machine learning play in elimination?

⚡ Accelerate the discovery of promising new compounds
🌍 Build a more inclusive global research community

Today, MMV and deepmirror convened more than 40 scientists from around the world for a hands-on workshop in Geneva to co-create the Drug Design for Global Health (dd4gh) platform – an AI tool designed to accelerate drug discovery for malaria and other diseases.

By combining technical training, user feedback and a strong focus on equity, this partnership is helping ensure dd4gh meets the needs of scientists everywhere while supporting efforts to accelerate the fight against malaria.

Next step: a second workshop in Accra this December will engage Africa-based researchers to further shape dd4gh ahead of its planned launch in March 2026.

👉 Read more: bit.ly/46xigrJ

24/09/2025

Antimalarial drug resistance threatens the efficacy of today’s life-saving medicines. For Africa, this could mean up to 16 million additional malaria cases and 360,000 severe hospitalizations annually.

To counter this threat, we must do what it takes to extend the useful lifecycle of existing drugs, buying the time needed to develop the next generation of antimalarials.

One way MMV is working toward this goal is by developing new combinations of existing drugs to provide a stronger barrier against resistance. Together with a consortium of partners supported by Japan’s Global Health Innovative Technology (GHIT) Fund, we are now studying a novel triple artemisinin-based combination therapy (TACT) in a Phase 3 clinical trial.

The trial – conducted in Uganda, Rwanda, Nigeria, Angola and Thailand – has just recruited its first patient. This marks the first time a fixed-dose triple therapy will be evaluated for uncomplicated in adults, adolescents and children over 6 months.

👉 Learn how this partnership is tackling resistance:

A novel way to extend the lifecycle of current drugs in the face of growing resistance.

23/09/2025

A single dose, a stronger elimination strategy.

Today, we’re celebrating Peru’s adoption of single-dose tafenoquine, together with point-of-care quantitative G6PD testing, into its National Treatment Guidelines for adults with relapsing vivax malaria.

This marks a major milestone in Peru’s malaria elimination journey – a decision backed by extensive research from the PAVE-Peru study, led by MMV and Universidad Peruana Cayetano Heredia.

Peru now becomes the third country globally (after Brazil and Thailand) to expand its antimalarial toolbox with tafenoquine, which will not only bolster malaria elimination efforts in the country, but also build momentum across the region for simpler, more patient-friendly solutions to prevent relapse.

👉 Read more: bit.ly/3K9GWzj

19/09/2025

Webinar: Effective communication is a powerful tool to bridge the gap between research and health impact.

TDR, the Special Programme for Research and Training in Tropical Diseases, invites health researchers, programme implementers and frontline health professionals to a free webinar next week on turning research into real-world action.

Join on 25 September for expert perspectives on research communication and real-life success stories from health professionals.

During the event, TDR will also introduce its new Massive Open Online Course on research communication, which will enable researchers to:
🔹 Write plain language summaries
🔹 Conduct stakeholder mapping
🔹 Develop communication plans
🔹 Produce effective presentations
🔹 Develop and deliver “lightning” presentations
🔹 Craft elevator pitches
🔹 Share work on social media

Register here: bit.ly/4mjiMzA

18/09/2025

After decades of progress against , drug resistance, , weakened health systems and dwindling global commitment threaten to fuel a dangerous resurgence.

In an opinion piece for BMJ, Dr Jean Kaseya and Dr Nebiyu Dereje argue that this resurgence in Africa is an avoidable crisis, and that the response must be owned and led by Africans.

Read about the urgent need to protect progress against one of the world’s deadliest diseases, and Africa CDC’s five-point plan to guide a continent-wide response: bit.ly/42yYjzz

17/09/2025

Last week, The Global Fund released a new film celebrating the milestone of 70 million lives saved since 2002. It honours the lives saved, the frontline heroes who make it possible and highlights the urgency of reaching millions more.

17/09/2025

Are the mosquitoes that transmit changing with fluctuating climate conditions?

A first-of-its-kind study from the Institute of Tropical Medicine Antwerp used realistic climate simulations to find out. The results show that warmer, more variable climates can “reprogram” mosquito biology, making them more resilient and potentially altering transmission patterns.

The findings underscore an urgent reality: must be factored into every facet of malaria control and elimination strategies, including the innovative genetic tools in development.

Read the full article: bit.ly/46xVmBH

16/09/2025

To contain the next pathogen of pandemic potential, we must strengthen our fight against long-standing threats like , and .

In a piece for The Telegraph, Dr Ibrahima Socé Fall of the Institut Pasteur de Dakar warns that the next pandemic will likely begin on the fragile frontlines of global health, in places like rural Africa, where surveillance for emerging pathogens is often fragmented, underfunded or non-existent.

His recommendation? A two-in-one strategy: tackling today’s biggest killers while building the systems needed to detect and contain future outbreaks.

Read the full article to see how investing in African health and home-grown scientific leadership can strengthen global health security and help fight future pandemics:

We must recognise that the next pandemic is most likely to emerge in a region already burdened by infectious disease

15/09/2025

For MMV, gender equity is more than a core value; it’s a key driver of innovative science, stronger partnerships and greater impact.

Global 50/50 has published its annual report analyzing gender equality, fairness and equity in the global health system, and for the 4th consecutive year, MMV is classified as a ‘Very high performer’.

We’re proud of this recognition, and mindful that achieving the goal of equality and universal human rights is not easy, but essential to strengthening global health security. At MMV, we’re committed to pushing this goal forward.

Read our take on the report here report: bit.ly/4glIWAb